The Rush Biomarkers Core (RBC) provides investigators a cost-effective means to measure protein biomarkers (cytokines, growth factors, and autoantibodies) in a variety of matrices, including:
- Serum/ Plasma
- Synovial fluid
- Cerebrospinal fluid
- Tissue or cellular lysates
- Conditioned media from cultured cells
The primary technology used by the core is the Luminex xMAP immunobead platform that allows for the simultaneous quantification of up to 100 analytes using low microliter quantities of specimen.
We offer "one stop shopping" for a range of assays relevant to clinical trials including: early disease detection/screening, monitoring disease progression or response to specific therapies, and predicting patient outcome.
In addition, we are also partnered with the Rush Proteomics Core to help you discover and validate new biomarkers that may currently be unappreciated for their prognostic and/or predictive value.
Jeffrey A. Borgia, PhD - Director
The Rush Biomarkers Core Facility
536 Cohn Research Bldg.
1735 W. Harrison St.
Chicago, IL 60612